Shengyao Guangyan Pharmaceutical

Explore the latest insights on Shengyao Guangyan Pharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Shengyao Guangyan Pharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken
Company

Novo Nordisk Raises Full‑Year Guidance on Oral Wegovy Momentum – Q3 Revenue Grows 6% as China Sales Weaken

Novo Nordisk A/S (NYSE: NVO) reported third‑quarter 2026 revenue of DKK 79.20 billion (USD 12.03 billion), up 6% in Danish kroner and 4% at constant exchange rates (CER), as obesity‑drug…

Sanofi's Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps

Sanofi’s Dupixent Wins NMPA Approval in China for Adolescent and Adult CRSwNP – First Biologic to Cover Both Age Groups in Chronic Rhinosinusitis with Nasal Polyps

Bayer's Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Bayer’s Hyrnuo (Sevabertinib) Wins NMPA Approval in First‑Line HER2‑Mutant NSCLC – Oral TKI Moves Into Treatment‑Naive Patients on 75.3 % ORR from SOHO‑01

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties